A biopharmaceutical company that develops targeted drugs for hard-to-treat cancers, Nuvation Bio makes the oral lung-cancer medicine IBTROZI (taletrectinib), approved by U.S. regulators in 2025 for patients whose non-small cell lung cancer carries a specific ROS1 gene change. It was founded in 2018 by Dr. David Hung, the same doctor behind the prostate-cancer drugmaker Medivation. The name blends "Nu-" with "-vation," a nod to innovation and to Hung's earlier Medivation success.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +6.02M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.